These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 15182776)

  • 41. Clinical effects of initial 6 months monotherapy with bisoprolol versus enalapril in the treatment of patients with mild to moderate chronic heart failure. Data from the CIBIS III Trial.
    Dobre D; van Veldhuisen DJ; Goulder MA; Krum H; Willenheimer R
    Cardiovasc Drugs Ther; 2008 Oct; 22(5):399-405. PubMed ID: 18528751
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial.
    Castagno D; Jhund PS; McMurray JJ; Lewsey JD; Erdmann E; Zannad F; Remme WJ; Lopez-Sendon JL; Lechat P; Follath F; Höglund C; Mareev V; Sadowski Z; Seabra-Gomes RJ; Dargie HJ
    Eur J Heart Fail; 2010 Jun; 12(6):607-16. PubMed ID: 20354032
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comment on "Clinical trials update from the European Society of Cardiology meeting 2005: CIBIS-III, by JGF Cleland and others".
    Willenheimer R; Krum H; van Veldhuisen DJ; Funck-Brentano C; Erdmann E; Meyer WR;
    Eur J Heart Fail; 2006 Mar; 8(2):219-20. PubMed ID: 16488368
    [No Abstract]   [Full Text] [Related]  

  • 44. Anti-oxidative properties of beta-blockers and angiotensin-converting enzyme inhibitors in congestive heart failure.
    Chin BS; Langford NJ; Nuttall SL; Gibbs CR; Blann AD; Lip GY
    Eur J Heart Fail; 2003 Mar; 5(2):171-4. PubMed ID: 12644008
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [The use of cardioselective beta-adrenoblocker bisoprolol in patients with chronic heart failure].
    Ol'binskaia LI; Ignatenko SB
    Kardiologiia; 2003; 43(2):56-9. PubMed ID: 12913983
    [No Abstract]   [Full Text] [Related]  

  • 46. Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice.
    McMurray J; Cohen-Solal A; Dietz R; Eichhorn E; Erhardt L; Hobbs FD; Krum H; Maggioni A; McKelvie RS; Piña IL; Soler-Soler J; Swedberg K
    Eur J Heart Fail; 2005 Aug; 7(5):710-21. PubMed ID: 16087129
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Effect of long-term therapy with contemporary drugs on diastolic cardiac function in patients with chronic heart failure].
    Belousov IuB; Upnitskiĭ AA; Khanina NIu
    Kardiologiia; 2005; 45(2):26-32. PubMed ID: 15798702
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Angiotensin-converting enzyme inhibitors and survival in women and men with heart failure.
    Keyhan G; Chen SF; Pilote L
    Eur J Heart Fail; 2007; 9(6-7):594-601. PubMed ID: 17462947
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Clinical trial of the month. The CIBIS-II study].
    Kulbertus H
    Rev Med Liege; 1999 Feb; 54(2):128-9. PubMed ID: 10221068
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical trials update from the European Society of Cardiology Meeting 2005: CIBIS-III. Response to correspondence from R. Willenheimer et al.
    Dickstein K
    Eur J Heart Fail; 2006 Mar; 8(2):221-2. PubMed ID: 16488369
    [No Abstract]   [Full Text] [Related]  

  • 51. Bisoprolol vs. carvedilol in elderly patients with heart failure: rationale and design of the CIBIS-ELD trial.
    Düngen HD; Apostolović S; Inkrot S; Tahirović E; Krackhardt F; Pavlović M; Putniković B; Lainscak M; Gelbrich G; Edelmann F; Wachter R; Eschenhagen T; Waagstein F; Follath F; Rauchhaus M; Haverkamp W; Osterziel KJ; Dietz R;
    Clin Res Cardiol; 2008 Sep; 97(9):578-86. PubMed ID: 18542839
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Influence of age and in-patient care on prescription rate and long-term outcome in chronic heart failure: a data-based substudy of the EuroHeart Failure Survey.
    Hülsmann M; Berger R; Mörtl D; Pacher R
    Eur J Heart Fail; 2005 Jun; 7(4):657-61. PubMed ID: 15921808
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bisoprolol in chronic heart failure.
    Davis M
    Hosp Med; 2000 Feb; 61(2):120-3. PubMed ID: 10748791
    [TBL] [Abstract][Full Text] [Related]  

  • 54. NTproBNP-guided drug treatment for chronic heart failure: design and methods in the "BATTLESCARRED" trial.
    Lainchbury JG; Troughton RW; Frampton CM; Yandle TG; Hamid A; Nicholls MG; Richards AM
    Eur J Heart Fail; 2006 Aug; 8(5):532-8. PubMed ID: 16829189
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bisoprolol: a review of its use in chronic heart failure.
    McGavin JK; Keating GM
    Drugs; 2002; 62(18):2677-96. PubMed ID: 12466013
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Reduced costs with bisoprolol treatment for heart failure: an economic analysis of the second Cardiac Insufficiency Bisoprolol Study (CIBIS-II).
    Eur Heart J; 2001 Jun; 22(12):1021-31. PubMed ID: 11428837
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A management trial for Duchenne cardiomyopathy.
    Ishikawa Y; Bach JR; Ishikawa Y; Minami R
    Am J Phys Med Rehabil; 1995; 74(5):345-50. PubMed ID: 7576410
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Epidemiology and treatment of chronic heart failure; use of bisoprolol].
    Nagy V
    Orv Hetil; 2013 Nov; 154(44):1731-4. PubMed ID: 24161596
    [TBL] [Abstract][Full Text] [Related]  

  • 59. beta-blockers, angiotensin II, and ACE inhibitors in patients with heart failure.
    Campbell DJ; Aggarwal A; Esler M; Kaye D
    Lancet; 2001 Nov; 358(9293):1609-10. PubMed ID: 11716889
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Trend towards prolonged survival in bisoprolol-first (Concor) for heart-failure trial (CIBIS III).
    Cardiovasc J S Afr; 2005; 16(5):276; discussion 278-9. PubMed ID: 16307161
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.